Analysts predict that Epizyme Inc (NASDAQ:EPZM) will announce $1.13 million in sales for the current quarter, according to Zacks. Two analysts have issued estimates for Epizyme’s earnings. The highest sales estimate is $1.25 million and the lowest is $1.00 million. The business is scheduled to announce its next quarterly earnings report on Tuesday, May 14th.
According to Zacks, analysts expect that Epizyme will report full year sales of $7.77 million for the current financial year, with estimates ranging from $5.00 million to $15.00 million. For the next fiscal year, analysts anticipate that the company will report sales of $35.90 million, with estimates ranging from $5.18 million to $70.90 million. Zacks Investment Research’s sales averages are an average based on a survey of sell-side research analysts that follow Epizyme.
Epizyme (NASDAQ:EPZM) last released its quarterly earnings data on Tuesday, February 26th. The biopharmaceutical company reported ($0.29) EPS for the quarter, beating the consensus estimate of ($0.46) by $0.17.
Several equities research analysts recently commented on the company. BidaskClub raised Epizyme from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, April 10th. Roth Capital reaffirmed a “buy” rating on shares of Epizyme in a research report on Wednesday, February 27th. Oppenheimer dropped their price objective on Epizyme from $27.00 to $18.00 and set an “outperform” rating on the stock in a research report on Wednesday, February 27th. ValuEngine raised Epizyme from a “sell” rating to a “hold” rating in a research report on Wednesday, February 27th. Finally, Cowen reaffirmed a “buy” rating and set a $18.00 price objective on shares of Epizyme in a research report on Tuesday, February 26th. Three analysts have rated the stock with a hold rating, eight have issued a buy rating and one has given a strong buy rating to the stock. Epizyme presently has an average rating of “Buy” and a consensus target price of $18.40.
Shares of Epizyme stock traded up $0.06 during trading on Wednesday, hitting $12.68. 972,104 shares of the company’s stock traded hands, compared to its average volume of 892,587. Epizyme has a 1 year low of $5.14 and a 1 year high of $18.70. The stock has a market capitalization of $1.15 billion, a PE ratio of -7.37 and a beta of 3.14.
A number of large investors have recently made changes to their positions in EPZM. BlackRock Inc. boosted its position in Epizyme by 1.4% in the third quarter. BlackRock Inc. now owns 4,362,472 shares of the biopharmaceutical company’s stock worth $46,242,000 after purchasing an additional 58,752 shares during the last quarter. Dimensional Fund Advisors LP purchased a new position in Epizyme in the third quarter worth about $2,535,000. Point72 Asset Management L.P. boosted its position in Epizyme by 259.8% in the third quarter. Point72 Asset Management L.P. now owns 669,300 shares of the biopharmaceutical company’s stock worth $7,095,000 after purchasing an additional 483,300 shares during the last quarter. MetLife Investment Advisors LLC boosted its position in Epizyme by 50.5% in the third quarter. MetLife Investment Advisors LLC now owns 37,738 shares of the biopharmaceutical company’s stock worth $400,000 after purchasing an additional 12,663 shares during the last quarter. Finally, Thrivent Financial for Lutherans boosted its position in Epizyme by 85.2% in the third quarter. Thrivent Financial for Lutherans now owns 109,711 shares of the biopharmaceutical company’s stock worth $1,163,000 after purchasing an additional 50,478 shares during the last quarter. 72.63% of the stock is currently owned by institutional investors and hedge funds.
Epizyme, Inc, a late-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases primarily in the United States. The company's lead products candidate is tazemetostat, an inhibitor of the EZH2 histone methyltransferase, which is in the Phase II clinical trial for patients with relapsed or refractory non-hodgkin lymphoma (NHL); Phase II clinical trial for relapsed or refractory patients with mesothelioma characterized by BAP1 loss-of-function; and Phase II clinical trial for adults and Phase I clinical trial for children with epithelioid sarcoma and other INI1-negative solid tumors.
Read More: What is a Fiduciary?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Epizyme Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epizyme and related companies with MarketBeat.com's FREE daily email newsletter.